Abstract
Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 206-218 |
| Number of pages | 13 |
| Journal | Prostate Cancer and Prostatic Diseases |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2011 |
Fingerprint
Keywords
- castrate-resistant prostate cancer
- clinical trials
- drug development
- novel therapies
ASJC Scopus subject areas
- Oncology
- Urology
- Cancer Research
Cite this
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. / Antonarakis, Emmanuel; Armstrong, A. J.
In: Prostate Cancer and Prostatic Diseases, Vol. 14, No. 3, 09.2011, p. 206-218.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
AU - Antonarakis, Emmanuel
AU - Armstrong, A. J.
PY - 2011/9
Y1 - 2011/9
N2 - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
AB - Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
KW - castrate-resistant prostate cancer
KW - clinical trials
KW - drug development
KW - novel therapies
UR - http://www.scopus.com/inward/record.url?scp=80054749674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054749674&partnerID=8YFLogxK
U2 - 10.1038/pcan.2011.24
DO - 10.1038/pcan.2011.24
M3 - Article
VL - 14
SP - 206
EP - 218
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
SN - 1365-7852
IS - 3
ER -